Your session is about to expire
← Back to Search
Fluorothymidine (FLT) for Graft-versus-Host Disease
Study Summary
This trial is testing a new way to give the stem cells that may help prevent GVHD while still allowing the new cells to attack the cancer cells.
- Graft-versus-Host Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any existing openings for participants in this research study?
"Clinicaltrials.gov states that this particular medical trial is not presently enrolling patients, despite its first posting dating back to January 1st 2017 and last update on March 21st 2022. However, 181 alternative studies are currently taking part in recruitment efforts."
Are individuals aged 40 and above eligible for inclusion in this research?
"As indicated by the eligibility requirements, individuals aged 18 to 99 can apply for this trial. If an applicant is younger than 18 or older than 65, they may be eligible for one of 67 trials targeting minors or 156 studies recruiting senior citizens respectively."
Is this the first instance of research like this?
"Fluorothymidine (FLT) has been the subject of research since 2014, when GenVivo Inc. sponsored its first study involving 122 participants. After receiving Phase 1 drug approval in 2014, numerous active trials have been launched across 12 cities and 5 countries to further explore FLT's efficacy."
What other experiments have used Fluorothymidine (FLT) to measure outcomes?
"Currently, 12 clinical studies are in progress to research Fluorothymidine (FLT). Of those trials, none have reached the third stage of testing. Buffalo, New york is home to several such tests while 29 other medical sites around the United States also host these investigations."
What results are researchers expecting to observe from the trial?
"Over the 35 day duration of this trial, researchers aim to gauge Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites. Additionally, they will be monitoring Strength of the FLT-PET Signal and Bone Marrow Cellularity in allogeneic stem cell transplant recipients as well as any Differences in FLT Uptake between Autologous HSCT and Allogeneic HSCT Patients, plus isolated/asymmetric Foci of Increased FLT relative to disease relapse incidence by Day +100 for allogeneic stem cell transplant patients."
Is my candidacy suitable for inclusion in this research?
"This clinical trial seeks to enlist 15 individuals with graft vs host disease, ranging from 18 to 99 years old. To qualify for the study, candidates must meet specific criteria such as undergoing autologous bone marrow transplant for multiple myeloma and being in a complete morphologic remission prior to allogeneic transplantation when receiving either chemotherapy or total body irradiation conditioning regimen alongside stem cells from matched related/unrelated or mismatched related (including haplotype-matched) donors."
How many individuals have been recruited for this experiment?
"This clinical trial is no longer enrolling patients, as the last edit was made on March 21st 2022. If you are seeking alternative trials, there are currently 169 studies for graft vs host disease and 12 for Fluorothymidine (FLT) actively admitting participants."
Share this study with friends
Copy Link
Messenger